Focusing on the interplay between host factors and viruses
The research in my laboratory mainly focuses on the interplay between host factors and two prime human threats – the human immunodeficiency virus (HIV) and the hepatitis C virus (HCV). More than 33 million people are living with HIV and approximately 2.5 million people are newly infected per year. An estimated 170 million people worldwide are chronically infected with HCV and more than 350,000 people die from HCV-related liver diseases each year. In the absence of vaccine for both HIV and HCV, there is an urgent need to develop new antiviral therapies to treat people, who are already infected, or to develop new approaches to interrupt viral transmission. A main goal in our laboratory is to identify host factors critical for HIV or HCV replication and to exploit them as targets for the development of novel antiviral therapies.
Ph.D., University of Lausanne 1993
1997-2017 Professor of Immunology and Microbial Science, Immunology and Microbial Science (IMS), The Scripps Research Institute
de Witte, L., Bobardt, M.D., Chatterji, U., Degeest, G., David, G., Geijtenbeek, T.B.H., and Gallay, P. A. 2007. Syndecan-3 is a dendritic cell-specific attachment receptor for HIV-1. Proc. Natl. Acad. Sci. 104: 19464-9.
Bobardt, M., Cheng, G., de Witte, L., Selvarajah, S., Chatterji, U., Beer, B., Geijtenbeek, T. B. H., Chisari, F. V., and Gallay, P. A. 2008. Hepatitis C virus NS5A anchor peptide disrupts human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 105: 5525-30.
Chatterji, U., Bobardt, M., Selvarajah, S., Yang,F., Tang, H. Sakamoto, N Vuagniaux, G., Parkinson, T., and Gallay, P. 2009. The isomerase active site of cyclophilin A is critical for hepatitis C virus replication. J. Biol. Chem. 284:16998-7005.
Hopkins, S., DiMassimo, B, Rusnak, P., Heuman, D., Lalezari, J., Sluder, A., Scorneaux, B., Mosier, S., Kowalczyk, P., Ribeill, Y., Baugh, J., and Gallay, P.A. 2012. The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection. J. Hepatol. 57:47-54.
Maskiewicz, R., Bobardt, M., Chatterji, U., Gunaseelan, S., Dezzutti, C.S., Penin, F., and Gallay, P.A. 2012. Sublimable C5A delivery provides sustained and prolonged anti-HIV microbicidal activities. Antimicrob. Agents Chemother. 56:3336-43.
Lim, P.J., Chatterji, U., Cordek, D., Sharma, S.D., Garcia-Rivera, J.A., Cameron, C.E., Lin, K., Targett-Adams, P., and Gallay, P.A. 2014. Correlation between NS5A dimerization and hepatitis C virus replication. J. Biol. Chem. 287:308611-73.
Bobardt, M., Hopkins, S., Baugh, J., Chatterji, U., Hernandez, F., Hiscott, J., Sluder, A., Lin, K., and Gallay, P.A. 2013. HCV NS5A and IRF9 compete For CypA binding. J. Hepatol. 58:16-23.
Gallay, P.A., Ptak, R.G., Bobardt, M.D, Dumont, J.-M., Vuagniaux, G. and Rosenwirth, B. 2013. Correlation of naturally occurring HIV-1 resistance to DEB025 with capsid amino acid polymorphisms. Viruses 5:981-97.
Gawlik, K., Baugh, J., Chatterji, U., Lim, P.J., Bobardt, M.D., and Gallay, P.A. 2014. HCV Core residues critical for infectivity are involved in core-NS5A interactions. PLoS One. 9(2):e88866.
Chatterji, U., Garcia-Rivera, J.A., Baugh, J., Gawlik, K., Wong, K.A., Zhong, W., Brass, C.A., Naoumov, N.V. and Gallay, P.A. 2014. The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance. Antimicrob Agents Chemother. 58(6):3327-3334.